Health and Healthcare

Gilead Sciences : GILD

All Gilead Sciences Articles

736 Articles

Chris Lange | Jul 13, 2015 at 7:55 AM EDT

Short Sellers Back Off Big Biotech

24/7 Wall St. has reviewed the short interest in top biotech companies, without focusing on speculative companies.

Chris Lange | Jul 6, 2015 at 1:45 PM EDT

Is Gilead Headed Lower From Here?

Merrill Lynch recently updated its view on Gilead Sciences, maintaining its Underperform rating for the stock but raising its price…

Chris Lange | Jun 25, 2015 at 7:50 AM EDT

Short Sellers Get More Selective on Big Biotech

The short interest data are out for the June 15 settlement date, and overall, short interest in the selected biotech…

Chris Lange | Jun 10, 2015 at 7:55 AM EDT

Short Sellers Lose Some Conviction Against Big Biotech

The May 29 short interest data have been compared with the previous figures, and for most of the selected biotech…

Chris Lange | May 28, 2015 at 8:25 AM EDT

Short Sellers Get Even More Ambitious Against Biotech Leaders

The short interest data are out for the May 15 settlement date. Biotech companies are considered a riskier group of…

Chris Lange | May 24, 2015 at 9:15 AM EDT

Large Companies With Fastest Revenue and Earnings Growth in 2015

S&P Capital IQ released a report regarding the performance of companies in terms of earnings and revenue.

Jon C. Ogg | May 23, 2015 at 9:30 AM EDT

The Most Loved Biotechs of Big Hedge Funds

There were some interesting positions of hedge funds in biotech, long and short, from the Goldman Sachs Hedge Fund Trend…

Jon C. Ogg | May 21, 2015 at 8:05 AM EDT

10 Companies to Own for the Next Decade

Back in November of 2010, 24/7 Wall St. first issued a list of stocks to own for the next decade.…

Jon C. Ogg | May 14, 2015 at 1:00 PM EDT

Key Dalio and Bridgewater Position Changes: Alcoa, Apple, CenturyLink, Cisco, Gilead, Emerging Markets

It turns out that hedge fund Bridgewater Associates and founder Ray Dalio have made some changes since the end of…

Chris Lange | May 12, 2015 at 8:05 AM EDT

Short Sellers Start to Get Nervous on Biotech

The short interest data are out for the April 30 settlement date, and for most of the selected biotech stocks,…

Chris Lange | Apr 30, 2015 at 4:30 PM EDT

Gilead Avoids the Earnings Hangman

Gilead Sciences reported better than expected first-quarter results Thursday after the markets closed.

Chris Lange | Apr 29, 2015 at 3:33 PM EDT

What to Expect From Gilead Earnings

ThinkstockGilead Sciences Inc. (NASDAQ: GILD) will report its first-quarter earnings Thursday after the markets close. Thomson Reuters has consensus estimates…

Chris Lange | Apr 27, 2015 at 8:30 AM EDT

Short Sellers Become More Wary of Big Biotech

The short interest data are out for the April 15 settlement date. 24/7 Wall St. has reviewed the top biotech…

Chris Lange | Apr 8, 2015 at 1:10 PM EDT

Opposing Views on Gilead Hepatitis C Presentation

Gilead Sciences is a major biotech involved with the EASL conference, and two analysts are calling heads and tails in…

Lee Jackson | Apr 1, 2015 at 9:15 AM EDT

5 Stocks to Buy for Big Revenue Growth

In a new research note, Jefferies reviewed the 12-month change in revenue growth for the largest 30 companies in the…

1 … 31 32 33 34 35 … 50

Gilead Sciences : GILD

All Gilead Sciences Articles

Short Sellers Back Off Big Biotech

Is Gilead Headed Lower From Here?

Short Sellers Get More Selective on Big Biotech

Short Sellers Lose Some Conviction Against Big Biotech

Short Sellers Get Even More Ambitious Against Biotech Leaders

Large Companies With Fastest Revenue and Earnings Growth in 2015

The Most Loved Biotechs of Big Hedge Funds

10 Companies to Own for the Next Decade

Key Dalio and Bridgewater Position Changes: Alcoa, Apple, CenturyLink, Cisco, Gilead, Emerging Markets

Short Sellers Start to Get Nervous on Biotech

Gilead Avoids the Earnings Hangman

What to Expect From Gilead Earnings

Short Sellers Become More Wary of Big Biotech

Opposing Views on Gilead Hepatitis C Presentation

5 Stocks to Buy for Big Revenue Growth

Tilray Jumps 6%, Canopy Growth Climbs 3%, Aurora Cannabis Gains 4%: Here’s Why TLRY Is Still Down 47% YTD

A Top Strategist Says Buy “Anything but the S&P 500” as Small Caps Quietly Steal the Lead

He Retired From Lobstering, Bought a Deli, and Left the Profit in the Business. Social Security Counted It Anyway.

He Retired From Lobstering, Bought a Deli, and Left the Profit in the Business. Social Security Counted It Anyway.

Company Stock in a 401(k) Gets a Special Tax Break. One Standard Rollover Erases It Forever.

Tilray Jumps 6%, Canopy Growth Climbs 3%, Aurora Cannabis Gains 4%: Here’s Why TLRY Is Still Down 47% YTD

A Top Strategist Says Buy “Anything but the S&P 500” as Small Caps Quietly Steal the Lead

Gilead Sciences : GILD

All Gilead Sciences Articles

Short Sellers Back Off Big Biotech

Is Gilead Headed Lower From Here?

Short Sellers Get More Selective on Big Biotech

Short Sellers Lose Some Conviction Against Big Biotech

Short Sellers Get Even More Ambitious Against Biotech Leaders

Large Companies With Fastest Revenue and Earnings Growth in 2015

The Most Loved Biotechs of Big Hedge Funds

10 Companies to Own for the Next Decade

Key Dalio and Bridgewater Position Changes: Alcoa, Apple, CenturyLink, Cisco, Gilead, Emerging Markets

Short Sellers Start to Get Nervous on Biotech

Gilead Avoids the Earnings Hangman

What to Expect From Gilead Earnings

Short Sellers Become More Wary of Big Biotech

Opposing Views on Gilead Hepatitis C Presentation

5 Stocks to Buy for Big Revenue Growth

Tilray Jumps 6%, Canopy Growth Climbs 3%, Aurora Cannabis Gains 4%: Here’s Why TLRY Is Still Down 47% YTD

A Top Strategist Says Buy “Anything but the S&P 500” as Small Caps Quietly Steal the Lead

He Retired From Lobstering, Bought a Deli, and Left the Profit in the Business. Social Security Counted It Anyway.

Featured Reads

He Retired From Lobstering, Bought a Deli, and Left the Profit in the Business. Social Security Counted It Anyway.

Company Stock in a 401(k) Gets a Special Tax Break. One Standard Rollover Erases It Forever.